The interrelationship between insulin resistance and Alzheimer development

Doaa A. Ghareeb*, Shimaa Mohamed, Mohamed El-Sayed

Biochemistry Department, Faculty of Science, Alexandria University, Alexandria, Egypt
Email: *d.ghareeb@yahoo.com, doaa.ahmed@alex-sci.edu.eg

Received 8 March 2013; revised 20 April 2013; accepted 10 May 2013

Copyright © 2013 Doaa A. Ghareeb et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT
Abnormalities in insulin metabolism, characteristic of T2DM, are among the major factors thought to mechanistically influence the onset of AD. These abnormalities are thought to play a role in AD via their influence on the synthesis and degradation of Aβ and as a consequence of the cascade of neuronal alterations resulting from the effects of danger/alarm signals from oligomeric amyloid species. Additionally, recent studies have indicated that certain signal transduction pathways downstream of the InsR may also promote the generation of Aβ peptides by modulating the cleavage of the parent Aβ precursor protein (AβPP) at the γ-secretase site, a cleavage site necessary for Aβ amyloidogenicity. Glucose homeostasis is critical for energy generation, neuronal maintenance, neurogenesis, neurotransmitter regulation, cell survival and synaptic plasticity. It also plays a key role in cognitive function. In an insulin resistance condition, there is a reduced sensitivity to insulin resulting in hyperinsulinemia; this condition persists for several years before becoming full blown diabetes. Toxic levels of insulin negatively influence neuronal function and survival, and elevation of peripheral insulin concentration acutely increases its cerebrospinal fluid (CSF) concentration. Peripheral hyperinsulinemia correlates with an abnormal removal of the amyloid beta peptide (Aβ) and an increase of tau hyperphosphorylation as a result of augmented cdk5 and GSK3β activities. This leads to cellular cascades that trigger a neurodegenerative phenotype and decline in cognitive function. Chronic peripheral hyperinsulinemia results in a reduction of insulin transport across the BBB and reduced insulin signaling in brain, altering all of insulin’s actions, including its anti-apoptotic effect. However, the increase in brain insulin levels resulting from its peripheral administration at optimal doses has shown a cognition enhancing effect on patient with AD.

Keywords: Insulin Resistance; B-Amyloid; Oxidative Stress; Brain Inflammation

1. INTRODUCTION
Insulin Resistance
Clamp studies [1,2] have demonstrated IR in both muscle and adipose tissues. Abnormalities in substrates particularly free fatty acids (FFAs), and the deposition of ectopic fat in muscle [3,4] as well as a number of cytokines such as tumor necrotic factor alpha (TNF-α) and interleukin-6 (IL-6) have been proposed as mediators of IR, although the precise mechanism remains incompletely defined [5,6].

Mechanisms of Insulin Resistance
Glucose transporter-4 (GLUT-4) is stored in intracellular vesicles. Insulin binds to its receptor in the plasma membrane, resulting in phosphorylation of the receptor and activation of insulin-receptor substrates (IRS) molecules. These substrates form complexes with docking proteins such as phosphoinositide-3 kinase (PI3K) at its 85-kDa subunit (p 85) by means of SH2 (Scr homology region 2) domains. Then p 85 is constitutively bound to the catalytic subunit (p 110). Activation of PI3K is a major pathway in the mediation of insulin-stimulating glucose transport and metabolism. It activates phosphoinositide-dependent kinases that participate in the activation of protein kinase B (PKB or Akt) and atypical forms of protein kinase C (PKC). This process results in the translocation of the glucose transporter to the plasma membrane. Exercise stimulates glucose transport by pathways that are independent phosphoinositide-3 kinase and that may involve 5'-AMP-activated kinase (AMPK) as shown in Figure 1 [7,8].
The abnormalities in glucose uptake into the cell appear to result from defects in intracellular signaling. A number of acquired factors including hyperinsulinemia, hyperglycemia, TNF-α, and FFAs, ceramide and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) have been implicated in altering insulin signaling in patients with obesity and type 2 diabetes [8,9].

The most likely mechanism of IR within the muscle cell is cytokine induced serine rather than tyrosine phosphorylation of IRS-1 [11]. A similar abnormality of IRS-2 in the hepatocyte is also likely to be an important mediator of IR with the liver [12,13].

Understanding the intracellular signaling of insulin pathways may lead to new approaches to the treatment of IR and presumably NAFLD. The recent proposal that IR syndrome could be an inflammatory disorder may be particularly relevant [14]. The balance between pro-inflammatory and anti-inflammatory cytokines derived from adipocytes and other tissue may determine the development of IR. Data regarding the mechanism of actions and the beneficial effects of peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists [15,16] and long chain polyunsaturated fatty acids [17] give credence to the inflammatory nature of IR. The recent report that salicylates or disruption of inhibitor of nuclear factor kappa-B kinase subunit beta (IKK-β) reversed obesity and diet-induced insulin resistance gives further support to this concept [18].

Although hyperinsulinemia is a common finding in NAFLD, it is often overlooked in its pathophysiology. However, insulin may injure the liver both directly and indirectly [19,20]. Patients undergoing chronic ambulatory peritoneal dialysis develop hepatic steatosis, but only when insulin is added to the peritoneal fluid dialysate [21,22]. Interestingly, the steatosis only develops at the surface of the liver and in some instances has the histologic appearance of NASH [21]. This direct effect may be due to insulin’s ability to generate oxidative stress [20] or up-regulation of the lipogenic protein, sterol regulatory elemental binding protein (SREBP) [23]. It also appears to have direct profibrogenic effects by stimulating connective tissue growth factor, especially in the presence of hyperglycemia [24].

This latter explanation may explain the observation that NAFLD patients with type 2 diabetes mellitus (T2-DM) have a particularly poor prognosis [25-27]. Evidence [28] also indicates that insulin may be directly involved in causing endoplasmic reticulum stress along with the unfolding protein response and apoptosis. This in itself may exacerbate insulin resistance [29-31] (Figure 2).

2. INSULIN AND BRAIN FUNCTION

2.1. Glucose & Insulin Signaling

2.1.1. Insulin and Insulin Receptor

The effects of insulin on the central nervous system (CNS) are affected by its availability to this separate physiological compartment. The term blood-brain barrier (BBB) in its most restrictive sense refers to the vascular...
Insulin receptors are present in the CNS, and were localized for the first time by ligand autoradiography and confirmed by immunohistochemistry and autoradiography [44-46]. CNS insulin receptors differ from their peripheral counterparts both in structure, function, and molecular weight [47]. Insulin receptors are widely distributed in the brain with the highest concentration in the olfactory bulb, hypothalamus, cerebral cortex, cerebellum and hippocampus. They are expressed in all regions of brain in both neurons and glial cells. Insulin receptors are distributed throughout the neuronal processes and the cell body, but are concentrated in the synaptic endings [48-52].

The signaling and biological effects of the insulin have been widely studied mainly in the classical insulin target tissues, e.g. liver, fat and skeletal muscle, with respect to glucose uptake, regulation of cell proliferation, gene expression and the suppression of hepatic glucose production [48]. However, insulin plays many roles within the CNS. It has been shown that some of the CNS effects of insulin are the opposite of those exerted in peripheral tissues. In particular, CNS insulin increases glucose and inhibits feeding, whereas serum insulin decreases glucose and increases feeding [40,53]. Thus, to some extent, insulin acts as its own counter regulatory hormone, with CNS insulin producing features of IR [32]. Thus, in the CNS, insulin participates in the regulation of feeding behavior and energy homeostasis, neuronal maintenance, neurogenesis, and neurotransmitter regulation. In addition, it has a role on cognitive functions as supported by neuronal activity, and in the control of aging-related processes [54].

2.1.2. Glucose, Insulin and Cognition

The brain consumes metabolic energy disproportionate to its size. It uses glucose (primary fuel), largely through oxidative metabolism. Glucose deprivation leads to coma, seizures, and produces potentially permanent brain damage. Glucose is continually supplied from cerebral blood flow and must be transported into the brain through the endothelial cells that form the BBB to reach neurons and glial cells by facilitated diffusion. Carriers of glucose are the glucose transport proteins (GLUT), which allow glucose entry into individual cells (neurons and glial cells) [55]. Animal models show that the cerebral blood flux depends on glucose levels in the blood stream; there is a compensatory mechanism to maintain adequate delivery of glucose fuel to the brain [56,57].

Evidence suggests regionally specific effects of insulin on brain glucose metabolism. Insulin does not seem to influence basal cerebral glucose metabolism or transport of glucose into the brain [58-63]. Insulin affects the use of glucose in specific regions of the brain, most likely by selective distribution of insulin-sensitive GLUT isoforms, which overlap with the distribution of insulin and InsR in the brain [64-67]. Insulin, through the InsR localized in the hypothalamus, contributes to the regulation of food intake and energy homeostasis and leads to changes in body weight by anorexigenic or orexigenic effects produced by increasing or decreasing levels of insulin in brain respectively. Moreover, insulin in the CNS modifies peripheral glucose metabolism by increasing insulin sensitivity in peripheral tissue [36,68,69].

In brain, insulin is not a major regulator of glucose metabolism. In vitro studies showed that insulin regulates glucose uptake of glial cells, but did not influence neuronal glucose uptake [70,71]. Insulin can influence neurons directly by mechanisms unrelated to modulation of glucose uptake. Neurotransmitter release, neuronal-outgrowth, tubulin activity, neuronal survival and synaptic plasticity are all directly modulated by insulin [72-75].

Studies in human and animal models have shown that an increase in brain insulin has a cognition-enhancing effect, independently of changes in peripheral glucose [76-80].

Moreover, there is cumulative evidence to support the effects of insulin and InsR on cognition, mediated by a...
modulatory role in learning and memory processes [48, 54, 72, 81, 82]. Insulin also modulates CNS concentration of neurotransmitters associated with important roles in cognition such as acetylcholine (ACh), norepinephrine and dopamine [83, 84]. It has been shown that, in an early stage of memory formation, an alteration of gene expression of InsR in the rat hippocampus in response to learning experiences occurs [85]. Taken together, all these findings suggest that insulin may influence normal memory function.

The biological basis of learning and memory processes resides in synaptic strength, where insulin signaling plays a modulator role on synaptic long-term potentiation (LTP) and long-term depression (LTD), two opposite forms of activity-dependent synaptic modifications. Insulin signaling modulates synaptic plasticity by: 1) Promoting the recruitment of γ-aminobutyric acid (GABA) receptors on post-synaptic membranes; 2) Influencing N-Methyl-D-aspartate (NMDA) receptor conductance (neuronal calcium ion (Ca\(^{2+}\) influx); and 3) Regulating 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid (AMPA) receptor cycling [86-92].

2.2. Hyperinsulinemia/Hyperglycemia in Brain

Alterations in circulating glucose levels can negatively affect the CNS because neurons have a consistently high glucose demand. Neuronal glucose uptake depends on extracellular glucose concentration, but chronic hyperglycemia results in cellular damage (glucose neurotoxicity). Therefore, a tight metabolic control is very important [93-95]. Studies on hyperglycemic rodents have shown cognitive impairment in addition to functional and structural alterations in the brain [94].

A growing body of evidence suggests that peripheral insulin abnormalities increase the risk for memory loss.
and neurodegenerative disorders such as Alzheimer’s disease (AD), but acute and chronic hyperinsulinemia have opposing effects on memory performance (Figure 4). A possible explanation for that is discussed below. Chronic hyperinsulinemia has a negative influence on memory, since T2DM has been associated with long-term impairment in cognitive function in humans and animal model studies.

On the other hand, acute increases of peripheral or brain insulin have an enhanced memory performance [76,78,96-100]. Prediabetic conditions with hyperinsulinemia but not chronic hyperglycemia may persist for many years before progression to T2DM. Hyperinsulinemia exposes the cells including neurons to unphysiologically high levels of insulin for a long period of time. Studies have shown that high concentrations of insulin affect the function and survival of neurons in culture by sensitizing them to toxin and stress-induced insults [101].

Moreover, a relationship between glycosylation of tau-proteins, its aggregation ability and the neurodegenerative phenotype has been revealed [102]. Peripheral injection of high doses of insulin in mice caused a rapid and dose-dependent increase in tau phosphorylation in the CNS [103]. In vitro studies indicate that insulin modulates the levels of amyloid-beta (Aβ) peptide by promoting the release of intracellular Aβ. Physiological insulin levels promote Aβ clearance by peptide degradation, a mechanism that involves insulin degrading enzyme (IDE) activity [104-106]. A low level of insulin in brain reduces Aβ release from intracellular to extracellular compartments and high levels reduce Aβ degradation in the extracellular compartment [107-111].

Impaired verbal memory has been reported in individuals with hyperinsulinemia and not chronic hyperglycemia [112]. Epidemiological studies have indicated that hyperinsulinemia, independent of glucose levels, constitutes one of the risk factors for dementia in the T2DM population as well as in the non-diabetic population, since the raising of peripheral insulin concentration acutely increases its concentration in the cerebrospinal fluid (CSF) and brain [96,97,113,114]. Prolonged peripheral hyperinsulinemia down-regulates BBB functions and the InsR activity and reduces insulin transport into the brain [114,115]. Thus, hyperinsulinemia during the development of T2DM is neurotoxic. Development of these complications depends on the duration of a diabetic condition, up regulation of circulating glucose, glycosylated proteins, etc., and the quality of metabolic control [93].

IR, hyperinsulinemia and T2DM are associated with elevated inflammatory markers and increased risk for AD [97,113,116-118] (Figure 3). In adults with T2DM and impaired glucose tolerance, an abnormal level of soluble tumor necrotic factor receptor-1 (TNF-R1) (death receptor domain) and tumor necrotic factor receptor-2 (TNF-R2) (cell survival domain) has been reported. Increased levels of TNF-R1 and decreased levels of TNF-R2 have also been observed in AD brain [119-121].

2.3. Impaired Glucose Uptake and Metabolism in the AD Brain

Studies using positron emission tomography (PET) have demonstrated that glucose metabolism is reduced markedly in the cerebral cortex in early stage AD and in the mild cognitive impairment (MCI) that is believed to be a precursor of AD, and that the reduction parallels the worsening of dementia symptoms, establishing that glucose uptake and metabolism are impaired in AD brain [122]. However, the causes of the impairment of glucose uptake/metabolism in AD brain are not well understood. Several findings suggest that this impairment is a cause, rather than a consequence, of neurodegeneration. The impaired cerebral glucose consumption is more severe than the impaired oxygen consumption in AD, suggesting that the former is not the result of the latter.

The brain is highly dependent upon glucose as a source of energy. The impaired glucose uptake/metabolism might lead to deficient synaptic activity and cellular homeostasis, as these are very sensitive to energy deficiency. Impaired glucose uptake/metabolism also causes reduced formation of acetyl-CoA and, consequently, affects the synthesis of Ach [123]. Deficient activity of the cholinergic system is one of the most significant biochemical deficiencies in AD pathology, discovered decades ago [124], and is the basis of the first generation of AD drugs, the cholinesterase (ChE) inhibitors donepecil,
galantamine and rivastigmine. The reduced cellular availability of acetyl-CoA may also cause decreased formation of both intracellular cholesterol and neurosteroids, which are the main lipid components of cell membranes. Membrane abnormalities have been observed in AD brains.

The Aβ peptide (or Aβ oligomers) has been shown to cause decreased glucose uptake/metabolism [125]. Furthermore, apolipoprotein E4 (ApoE4) and diabetes mellitus are known to be major risk factors for AD [126]. Individuals with ApoE4 alleles have lower brain glucose metabolism than those carrying ApoE2 or ApoE3 alleles. Diabetic patients are characterized by deficient glucose uptake/metabolism. Hence, it can be speculated that ApoE4 genotype together with diabetes may increase the risk for AD by impairment in brain glucose uptake/metabolism.

3. LINK BETWEEN IR AND AD

3.1. Relationships between IR and AD

Pathogenesis

Abnormalities in insulin metabolism, characteristic of T2DM, are among the major factors thought to mechanistically influence the onset of AD. These abnormalities are thought to play a role in AD via their influence on the synthesis and degradation of Aβ and as a consequence of the cascade of neuronal alterations resulting from the effects of danger/alarm signals from oligomeric amyloid species (Figure 3) [127]. Additionally, recent studies have indicated that certain signal transduction pathways downstream of the InsR may also promote the generation of Aβ peptides by modulating the cleavage of the parent Aβ precursor protein (AβPP) at the γ-secretase site, a cleavage site necessary for Aβ amyloidogenicity [128].

Although this evidence tentatively suggests that T2DM might play an important role in AD through mechanisms that involve Aβ peptide generation, alternative studies suggest that insulin may also provoke amyloid accumulation by limiting Aβ degradation via direct competition for the insulin degrading enzyme (IDE). Another major substrate of IDE is the Aβ peptide. The IDE degrades monomeric but not the oligomeric Aβ peptide [104,105]. IDE is a zinc-metalloproteinase that preferentially cleaves proteins with a propensity to form pleated sheet-rich amyloid fibrils, such as Aβ peptides. This relationship of IDE with Aβ is supported by recent evidence indicating that IDE activity in the brain is negatively correlated with Aβ content, and that IDE expression is decreased in the AD brain [110]. Insulin regulates the levels of IDE. Hyperinsulinemia reduces Aβ degradation by reduction of IDE levels and binding competition (Figure 3) [107-111].

It has been reported that Aβ-40 and Aβ-42 reduce insulin binding and InsR autophosphorylation. The reduction in this binding seems to be caused by a decrease in the affinity of insulin to the InsR. This suggests that Aβ is a direct competitive inhibitor of insulin binding and action [129], an aspect that demands further investigation.

The strikingly reduced CNS expression of genes encoding insulin, insulin-like growth factor-I (IGF-I), and insulin-like growth factor-II (IGF-II), as well as the insulin and IGF-I receptors in AD led to some authors to suggest that AD may represent a neuroendocrine disorder that resembles diabetes mellitus [130]. In addition, the same researchers demonstrated that alterations insulin levels and IGF expression and deterioration of insulin function with the course of AD progression, were linked with an ACh decrease in the brain [131]. There is evidence supporting the notion that high plasma insulin levels and peripheral IR affect Aβ-42 levels, inflammation in the CNS and cognitive performance of individuals [132]. From such evidence, a model can be constructed describing how this metabolic profile contributes to the pathogenesis of AD. There are several etiological factors leading to the final common expression in the AD pathology [131].

Insulin plays an important role in memory and brain function in general. Peripheral hyperinsulinemia and IR induce a number of deleterious effects in the CNS that interfere with these functions, in a manner that is exacerbated by obesity and aging. In particular, effects on Aβ regulation and neuroinflammation are potential culprits in promoting aging-related memory impairment in some cases of AD (Figure 3). This possibility has obvious relevance for adults with T2DM. However, it is worth noting that hyperinsulinemia and IR affect many non-diabetic adults with conditions such as obesity, impaired glucose tolerance, cardiovascular disease, and hypertension [133-135].

Indeed, in recent years, cumulative evidence has been gained on the involvement of alteration in neuronal lipoproteins activity, as well as a role of cholesterol and other lipids in the pathogenesis of this neurodegenerative disorder. In relation to hypercholesterolemia, several reports have shown that elevated serum cholesterol levels and elevated levels of Aβ are linked with AD risk. Cholesterol influences the activity of the enzymes involved in the metabolism of the amyloid precursor protein (APP) and in the production of Aβ, but the mechanism by which cholesterol affects Aβ production and metabolism is not fully understood [136].

3.2. Metabolomics of Insulin in the Context of Neuronal Survival and AD Onset

To understand the link between insulin, IR, neuronal
survival and AD onset, it is important to identify the link between the key molecules involved in the intracellular pathways utilized by insulin to exert its effect. IR in the periphery produces acute episodes of hyperinsulinemia without chronic hyperglycemia. High levels of insulin in plasma are correlated with high levels of insulin in brain [114] leading to neurotoxic effects [101].

Studies in transgenic mouse models of AD have shown that diet-induced peripheral IR promotes amyloidosis suggesting that peripheral IR can influence Aβ production in the brain [111,137]. These findings in association of a reduced basal signaling of insulin in cortex with an increased degree of AD neuropathology argue that peripheral insulin resistance promotes neuronal IR when genetic background predisposes to AD. However, further studies are necessary to clarify this.

Insulin binding to the InsR leads to autophosphorylation of the InsR which initiates several signaling cascades. One of these is the lipid kinase PI3K cascade, which is associated with almost all of the metabolic action of insulin. PI3K activation leads to the activation of PKB and glycogen synthase kinase 3 (GSK3). Activation of PKB inactivates GSK3 by phosphorylation [138,139]. The neuroprotective effect of IGF-I results from activation of PKB [140]. Expression of PKB protects neurons against toxin-induced death and protects PC12 cells against Aβ peptide-induced death [141-143].

IR in the periphery produces hyperinsulinemia, while in the brain it decreases IDE activity. The effects of IDE include abnormal Aβ removal and plaque formation, increased cell division protein kinase 5 (cdk5) activity, and increased activity of GSK3. Dysregulation of cdk5 is a major molecular event in the pathway to neurodegeneration [144-146]. GSK3 activity has been implicated in the pathology of AD in different ways. AD brain exhibits a dysregulated expression of this kinase as well as changes in its activity [147,148], leading to hyperphosphorylation of tau and tangle formation. Several studies have shown that GSK3 activity is required for induction of neuronal apoptosis, while inhibition of GSK3 promotes neuronal survival [72]. Insulin signaling induces the phosphorylation and inhibition of GSK3 [138].

All of the negative effects of hyperinsulinemia in the CNS and their associated functions could be exacerbated or similarly produced by a central IR in conjunction with the peripheral IR or secondary to it. This is supported by the evidence of central molecular IR in a mouse model of AD with induced peripheral IR, where a reduced basal signaling (reduced phosphorylation of IR, PKB and GSK3, as well as decreased PI3K activity) was shown in the cerebral cortex [111,137].

Studies of insulin action in brain are focused on the basic effects of insulin signaling. Insulin acts like a neurotrophic factor, since it promotes neuronal survival [75,149]. Studies in vitro of intracellular pathways utilized by insulin for synaptic plasticity have identified a link to neuronal protection against cell death [75,149]. Intracellular pathways utilized by insulin to influence synaptic plasticity and neuronal survival converge on the PI3K pathway [81]. The increased catalytic activity of PI3K results in the phosphorylation and activation of antiapoptotic substrates [81]. PKB is of major importance in mediating the effects of PI3K in neuronal survival, and in vitro and in vivo studies have shown that activated PKB protects against apoptosis.

4. ALZHEIMER’S DISEASE

Alzheimer’s disease (AD) is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory deterioration, progressive impairment of activities of daily living, and a variety of neuropsychiatric symptoms and behavioral disturbances. Prevalence studies suggest that in 2000 the number of persons with AD in the United States was 4.5 million [150]. The percentage of persons with AD increases by a factor of two with approximately every five years of age, meaning that 1% of 60-year-olds and about 30% of 85-year-olds have the disease [151]. Without advances in therapy, the number of symptomatic cases in the United States is predicted to rise to 13.2 million by 2050 [150].

The amyloid hypothesis states that formation of β-amyloid (Aβ) peptides by neurons is the prime trigger of the pathogenesis of AD, and during years Aβ deposition was considered to be the cause of the disease. Evidence supporting the amyloid hypothesis has been recently reviewed [152]. Aβ protofibrils activate microglia, inverting an inflammatory response and release of neurotoxins or neurotoxic cytokines [153].

4.1. Diagnosis

AD is the most common form of dementia in the elderly. Dementia is commonly recognized with use of the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) [154,155]. The diagnosis of AD is most often based on the criteria developed by the National Institute of Neurologic and Communicative Disorders and Stroke-AD and Related Disorders Association (NINCDS-ADRDA) [156], according to which the diagnosis is classified as definite (clinical diagnosis with histologic confirmation), probable (typical clinical syndrome without histologic confirmation), or possible (typical clinical features but no alternative diagnosis apparent; no histologic confirmation). Typical sensitivity and specificity values for the diagnosis of probable AD with the use of these criteria are 0.65 and 0.75, respectively [157].

The classic clinical features of AD are an amnesic type
of memory impairment [158,159], deterioration of language [160], and visuospatial deficits [161,162]. Motor and sensory abnormalities, gait disturbances, and seizures are uncommon until the late phases of the disease [156].

Functional and behavioral disturbances are characteristic of the disease. Patients progress from the loss of higher-level activities of daily living, such as check writing and the use of public transportation, through abnormalities of basic activities of daily living, such as eating, grooming, and using the toilet, as the disease enters advanced phases [163]. Behavioral disturbances also progress over the course of the illness [155]. Mood change and apathy commonly early and continue for the duration of the disease. Psychosis and agitation are characteristic of the middle and later phases of the disease [164].

As part of the assessment of dementia, laboratory studies are necessary to identify causes of dementia and coexisting conditions that are common in the elderly. Thyroid function tests and measurement of the serum vitamin B12 level are required to identify specific alternative causes of dementia. A complete blood count; measurement of blood urea nitrogen (BUN), serum electrolyte, and blood glucose levels; and liver-function tests should be performed [165]. Specialized laboratory studies such as a serologic test for syphilis, the erythrocyte sedimentation rate (ESR), a test for human immunodeficiency virus antibody, or screening for heavy metals are indicated when historical features or clinical circumstances suggest that infections, inflammatory diseases, or exposure to toxins may be contributing to the dementia.

Neuroimaging plays an important role in the diagnosis of AD and is particularly helpful in excluding alternative causes of dementia. It is recommended that patients undergo structural imaging of the brain with computed tomography (CT) or magnetic resonance imaging (Figure 5) at least once in the course of their dementia [165]. Functional imaging with PET (Figure 5) or single-photon-emission CT may be helpful in the differential diagnosis of disorders associated with dementia [166].

4.2. Pathophysiology

There is increasing consensus that the production and accumulation of Aβ peptide are central to the pathogenesis of AD [168]. Evidence supporting a pivotal role for Aβ includes the following: mutations in the gene encoding APP lead to early-onset AD; all currently known mutations associated with AD increase the production of Aβ; in patients with trisomy 21 (Down’s syndrome) and three copies of the gene for APP, neuropathological characteristics of AD develop by midlife; Aβ is neurotoxic in vitro and leads to cell death; over expression of human APP in transgenic mouse models of AD results in neuritic plaques similar to those seen in humans with AD; transgenic mice over expressing the human APP have evidence of learning and memory deficits, in concert with the accumulation of amyloid; the ApoE ε4 genotype, a major risk factor for AD, leads to accelerated deposition of amyloid; and the generation of antiamyloid antibodies in humans with AD seems to ameliorate the disease process [169-173] Formation of neurofibrillary tangles, oxidation and lipid peroxidation, glutamatergic excitotoxicity, inflammation, and activation of the cascade of apoptotic cell death are considered secondary consequences of the generation and deposition of Aβ [168] (Figure 6). This hypothesized amyloid cascade underlies attempts to modify the onset and course of AD through identification of antiamyloid agents, antioxidants, anti-inflammatory drugs, compounds that limit the phosphorylation of tau-protein, antiapoptotic agents, and glutamatergic N-methyl-aspartate receptor antagonists.

Cell dysfunction and cell death in nuclear groups of neurons responsible for maintenance of specific transmitter systems lead to deficits in acetylcholine, norepinephrine, and serotonin [174,175]. Alternate hypotheses regarding the pathophysiology of AD place greater emphasis on the potential role of tau-protein abnormalities, heavy metals, vascular factors, or viral infections.

4.3. Oxidative Damage and AD

4.3.1. Inflammation and AD

It has been speculated that this inflammatory response associated with the presence of neuritic plaques is secondary to Aβ accumulation and could be involved in neuronal damage and with the progression of the disease. Activated microglia and reactive astrocytes surrounding extracellular deposits of Aβ initiate an inflammatory re-
Figure 6. Putative amyloid cascade. This hypothesis of the amyloid cascade, which progresses from the generation of the $\alpha\beta$ peptide from APP, through multiple secondary steps, to cell death, forms the foundation for current and emerging options for the treatment of AD [167].

response characterised by a local cytokine-mediated acute phase response, activation of the complement cascade and subsequent further cell damage [176-178]. The main inflammatory players in AD are:

1) Microglia

Microglia constitute around 10% of the cells in the nervous system. They represent the first line of defense against invading pathogens or other types of brain tissue injury. Under pathological situations, such as neurodegenerative disease, stroke and tumor invasion, these cells become activated, surround damaged and dead cells and clear cellular debris from the area, like phagocytic macrophages of the immune system [179]. Activated microglia up-regulate a variety of surface receptors, including the major histocompatibility complex and complement receptors [180]. They also experience dramatic morphological changes from resting ramified cells to motile activated amoeboid microglia [181]. Once immunostimulated in response to neurodegenerative events, these microglia cells release a variety of proinflammatory mediators such as cytokines, ROS, complement factors, neurotoxic secretory products, free radical species and nitric oxide (NO) which all can contribute to both neuronal dysfunction and cell death, ultimately creating a vicious cycle [182].

Microglia has been suggested to be preferentially as-
associated with certain amyloid plaque types [183]. Aβ peptides and APP are potent glial activators [184,185] and disruption of APP gene and its proteolytic products delay and decrease microglial activation [186]. The extend of astrocytosis and microglial activation is directly dependent on the amyloid load, and treatment with β-sheet breakers peptide results in reduced brain inflammation [187]. Aβ is able to stimulate NF-κB-dependent pathway that is required for cytokine production [188]. The subsequent activation of extracellular signal-regulated kinase (ERK) and MAPK pathways by Aβ binding to the microglial cell surface induces proinflammatory gene expression and leads to the production of cytokines and chemokines [189]. Not only Aβ, but also the C-terminal 100 amino acids of β-APP, which are present also in senile plaques, can induce astrocytosis and neuronal death. The C-terminal 100 exposure results in activation of MAPK pathways as well as NF-κB [190]. On the other hand, other proteins involved in APP processing have been implicated in the inflammatory response. Loss of presenilin function in presenilin conditional knockout mice leads to differential up-regulation of inflammatory markers in the cerebral cortex, such as strong microglial activation, and elevated levels of glial fibrillary acidic protein (GFAP), complement component C1q, and cathepsin S [191]. This effect might not be directly related to APP metabolism, since presenilin has been also shown to interact with β-catenin and to be implicated in the cleavage of other type I transmembrane proteins, such as Notch, CD44, Ecadherin, receptor tyrosine-protein kinase erbB-4 (ErbB-4) and the Notch ligands [192]. In some situations the role of microglia has been found to be beneficial, since activated microglia can reduce Aβ accumulation by increasing its phagocytosis, clearance and degradation [105,193]. Secreted Aβ1-40 and Aβ1-42 peptides are constitutively degraded by neprilysin and IDE, a metalloprotease released by microglia and other neural cells, whose enzymatic activity is enhanced by inflammatory events, such as lipopolysaccharide (LPS) stimulation [104]. Microglia can also secrete a number of soluble factors, such as the glia-derived neurotrophic factor (GDNF), which are potentially beneficial to the survival of neurons [180].

2) Astrocytes

Astrocytes are known to be important for Aβ clearance and degradation, for providing trophic support to neurons, and for forming a protective barrier between Aβ deposits and neurons [194,195]. The presence of large numbers of astrocytes associated with Aβ deposits in AD suggests that these lesions generate chemotactic molecules that mediate astrocyte recruitment. Astrocytes throughout the entorhinal cortex of AD patients gradually accumulate Aβ-42 positive material and the amount of this material correlates positively with the extent of local AD pathology. Aβ-42 within astrocytes appears to be of neuronal origin, most likely accumulated via phagocytosis of local degenerated dendrites and synapses, especially in the cortical molecular layer [196] Figure 7.

Figure 7. Representation of the local inflammatory response by amyloid-beta. Staining of activated microglia and the recruitment of astrocytes in a neuritic plaque from the brain of an AD patient. Schematic representation of Aβ deposition, which promotes microglial activation and the recruitment of astrocytes, release of cytokines and cytotoxic molecules that are harmful for neurons. At the same time, microglia and astrocytes are able to phagocyte Aβ and to secrete IDE, which contribute to the clearance of Aβ [211].
4.3.2. Inflammatory Cytokines and Chemokines

Nearly all the cytokines and chemokines that have been studied in AD, including IL-1β, IL-6, TNF-α, IL-8, transforming growth factor-β (TGF-β) and macrophage inflammatory protein-1α (MIP-1α) seem to be up-regulated in AD compared with control individuals [200]. An association of AD with polymorphisms in a number of proinflammatory genes has been described, including IL-1 [201], IL-6 [202], TNF-α [203,204], and 1-antichymotrypsin, an acute phase protein [205]. Animal models of AD, such as Tg2567 over expressing APP enzyme 1 (BACE1 or β-secretase) in response to chronic stress [195]. Oxidative damage could be already an early event in the disease, even when there is no Aβ deposition [198]. In this line, a report has shown microglial activation in early stages of AD, comparing PET and volumetric magnetic resonance imaging (MRI) in patients with mild to moderate dementia with healthy individuals [199].

REFERENCES


Copyright © 2013 SciRes.


Journal of Biological Chemistry, 275, 4607-4612. doi:10.1074/jbc.275.7.4607


expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. *Brain Research*, **894**, 21-30. doi:10.1016/S0006-8993(00)03176-0

